Skip to main content

Table 1 Patient characteristics at first relapse/progression (n = 54)

From: Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis

 

No. of patients

Age, years

 Median (range)

73.5 (26–85)

  ≥ 65

46 (85.2%)

  < 65

8 (14.8%)

KPS

 Median (range)

60 (30–100)

  ≥ 70

15 (27.8%)

  < 70

39 (72.2%)

Gender

 Male

25 (46.3%)

 Female

29 (53.7%)

Cognitive impairment at diagnosis of relapse a

 Yes

30 (55.6%)

 No

24 (44.4%)

Hemiparesis at diagnosis of relapse

 Yes

12 (22.2%)

 No

42 (77.8%)

Seizures at diagnosis of relapse

 Yes

8 (14.8%)

 No

46 (85.2%)

Steroid use at diagnosis of relapse

 Yes

28 (51.9%), median dose 12 mg (range 2–24 mg)

 No

26 (48.1%)

Involvement of DBS

 Yes

38 (70.4%)

 No

16 (29.6%)

Distribution of lesions in cMRI

 Unifocal

22 (40.7%)

 Multifocal

30 (55.6%)

 Diffuse leptomeningeal

2 (3.7%)

CSF cytology

 Positive

4 (7.4%)

 Negative

13 (24.1%)

 Not done

37 (68.5%)

Charlson Comorbidity Index

 Score 0

35 (64.8%)

 Score ≥ 1

19 (35.2%)

Status before salvage treatment

 Relapse

31 (57.4%)

 Refractory

23 (42.6%)

Relapse/progression occurred in

 2006–2009

13 (24.1%)

 2010–2015

22 (40.7%)

 2016–2022

19 (35.2%)

  1. aPatients with cognitive impairment documented in neurological examination at relapse, no standardized neurocognitive or neuropsychological assessment was performed
  2. Abbreviations: CSF = cerebrospinal fluid, DBS = deep brain structures, KPS = Karnofsky performance score, MRI = magnet resonance imaging